The expansion of the North American IUD Market is mostly driven by increased knowledge of these devices' availability as a result of campaigns and internet ads.
Intrauterine Devices (IUDs) are little T-shaped devices that are implanted in the uterus of women to prevent conception. Two prominent devices on the market are hormone-based copper and hormone-based IUDs. Long-lasting, efficient at preventing pregnancy, simple to use and maintain, and cost-effective are some of the factors propelling the Intrauterine Contraceptive Devices market. The government's initiative in marketing the benefits of using IUDs has a significant impact on market demand.
Other factors driving the growth of the North American IUD market include an increase in the number of working-class women around the world, breakthroughs in IUD technology, an increase in the prevalence of sexually transmitted illnesses, and government funding.
The introduction of improved technologies and the launch of novel goods provide market growth potential. Raising awareness of these devices, even in developing nations, serves primarily to increase market demand. The rate of growth of the Intrauterine Contraceptive Devices market is also increasing due to ongoing research on producing new products. The North American intrauterine contraceptive devices (IUD) market is further predicted to develop over the forecast period, owing to improved healthcare infrastructure and increased population awareness.
Inadequate importance during conception consultations, a lack of correct understanding about the use of devices in rural areas, pelvic inflammatory infection, infertility concerns, ectopic pregnancy, and limited access to conception are all factors that are limiting the market's growth. Heavy bleeding, irregular bleeding, and cramping are anticipated to slow the growth of the intrauterine contraceptive devices market in North America. The North America intrauterine contraceptive devices market has a number of challenges, including a shortage of experienced workers in healthcare facilities. In March 2020, the WHO declared a public health emergency. Contraception and the sexual health market have suffered as a result of the COVID 19 pandemic.
This research report has been segmented and sub-segmented the North America intrauterine devices market into the following categories:
By End User:
The most valuable market for intrauterine contraceptive devices across the globe is likely to be in North America. Both hormone-free copper and hormone-based IUDs are in increasing demand in the United States. IUDs are one of the most effective kinds of reversible contraception, and they're becoming increasingly popular among both women and healthcare practitioners. In this region, the United States has the biggest market share. Demand for this region's market is increasing as a result of an increase in the number of young ladies. Approximately 62 million American women (15–44) took contraception during their reproductive years, according to a 2018 study titled "Contraceptive Use in the United States.". It is estimated that 43 million (70%) of them are at risk of unintended pregnancy, which means that they're sexually active but don't want to get pregnant. Those women may become pregnant if they don't use a contraceptive method effectively and consistently, according to the article.
The study by Amanda Black et al, published in the October 2020 issue of the Society of Obstetricians and Gynaecologists of Canada (SOGC), shows that Canadians who wish to avoid getting pregnant during the COVID-19 pandemic of 2020 will find it much more difficult because contraceptive care and methods are not available. Furthermore, social isolation may promote unplanned pregnancy owing to unprotected intercourse, reproductive coercion, and intimate personal assault.
KEY MARKET PLAYERS:
Some of the promising companies operating in the North America Intrauterine Devices Market are Agile Therapeutics, Actavis PLC, ANI Pharmaceuticals Inc., Bayer, Teva Pharmaceutical, Besins HealthCare, Brecuro Medical, Effik International, Eurogine, HLL Lifecare, HRA Pharma, Lupin Pharmaceuticals, Ltd, Okamato Industries, Inc., and Pfizer.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com